Prestige Brands Stands By Nix Lice 'Kill' Claims Despite NAD Rejection
This article was originally published in The Rose Sheet
Executive Summary
Prestige Brands declines to comply with NAD recommendations to discontinue “kill” claims for its Nix Ultra lice treatment product, arguing that “eliminating” lice infestation is tantamount to “killing” the bugs. In response, NAD refers the firm's ad claims to FTC.
You may also be interested in...
NAD Voice Muted In Deliberations On Appeals Of Its Decisions
The National Advertising Division changes its review process to allow opposing firms some control over scheduling in the process and in resolving their disputes. The changes, recommended by ABA committees, also impose fees for both firms in appeals and allow more time for compliance with decisions.
Lice Treatment Claims Require Tests On Humans, Not Just Bugs – NAD
NAD rejects TyraTech’s argument that because its Vamousse homeopathic works on lice and not people, non-human studies are adequate substantiation. Vamousse advertising referred to challenger Sanofi Pasteur’s Sklice prescription lice spray as less effective and more risky to human health.
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.